Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24699869 | 1.00 | MAPK1 (0.57) | MAPK1B4GALT1MEN1KMT2ALGALS8 | |
| SCHEMBL17283441 | 0.96 | MAPK1 (0.60) | MAPK1B4GALT1MEN1KMT2ALGALS8 | |
| SCHEMBL20985069 | 0.94 | MAPK1 (0.53) | MAPK1B4GALT1MEN1KMT2AHRAS | |
| SCHEMBL30980624 | 0.92 | MAPK1 (0.52) | MAPK1B4GALT1MEN1KMT2ALGALS8 | |
| SCHEMBL24239904 | 0.91 | LMNA (0.52) | MAPK1B4GALT1MEN1KMT2AHRAS | |
| SCHEMBL15499416 | 0.91 | MAPK1 (0.55) | MAPK1B4GALT1MEN1KMT2ALGALS8 | |
| SCHEMBL2003046 | 0.88 | LMNA (0.50) | MAPK1MEN1KMT2ALGALS8 | |
| SCHEMBL18756738 | 0.87 | HTT (0.50) | LGALS8 | |
| SCHEMBL23992233 | 0.86 | MAPK1 (0.60) | MAPK1B4GALT1MEN1KMT2ALGALS8 | |
| SCHEMBL18875811 | 0.85 | MAPK1 (0.67) | MAPK1B4GALT1MEN1KMT2ALGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| CN-114616332-A | GalNAc-oligonucleotide conjugates for delivery to liver and methods of making the same | 第一三共株式会社 | 2022-06-10 | — | — | CN | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | MAPK1 2230/4885B4GALT1 296/4885MEN1 3915/4885 |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | CSGALNACT1, GALNT6, GALNT14 | MAPK1 3804/4885B4GALT1 14/4885MEN1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.